文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急性胰腺炎患者30天内主要不良肾脏事件危险因素分析

[Analysis of risk factors of major adverse kidney events within 30 days in patients with acute pancreatitis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论入住时APACHE II评分、SOFA评分和高氯血症是急性胰腺炎患者30天内主要不良肾脏事件(MAKE30)的独立危险因素,基于三者的预测模型AUC为0.846。

该回顾性队列研究纳入2019年6月至2021年6月苏州大学附属第一医院首次确诊、发病<72小时的急性胰腺炎患者162例,按是否发生MAKE30分为MAKE30组(32例)与非MAKE30组(130例)。多因素Logistic回归显示,入住时APACHE II评分(OR=1.659,95%CI 1.426-1.956,P=0.009)、SOFA评分(OR=1.501,95%CI 1.236-1.840,P=0.014)和高氯血症(OR=1.858,95%CI 1.564-2.231,P=0.004)是MAKE30的独立危险因素。基于上述三项指标建立的回归方程预测MAKE30的AUC为0.846(95%CI 0.774-0.923,P=0.001)。高氯血症(Cl-≥110 mmol/L)组MAKE30和AKI发生率、BUN和SCr水平、住院及ICU天数、48和72小时累计静脉输液量均显著高于非高氯血症组(均P<0.01)。

要点

  • 入住时APACHE II评分(OR=1.659,95%CI 1.426-1.956,P=0.009)、SOFA评分(OR=1.501,95%CI 1.236-1.840,P=0.014)和高氯血症(OR=1.858,95%CI 1.564-2.231,P=0.004)是AP患者MAKE30的独立危险因素。
  • 基于APACHE II评分、SOFA评分和高氯血症的回归方程Logit(P)=0.063+0.525×APACHE II评分+0.328×SOFA评分+0.895×高氯血症预测MAKE30的AUC为0.846(95%CI 0.774-0.923,P=0.001)。
  • 入住血Cl-≥110 mmol/L的高氯血症组(n=19)MAKE30发生率68.4%、AKI发生率89.5%,分别高于非高氯血症组(n=143)的13.3%和43.4%。
  • 高氯血症组入住时BUN 9.3±2.5 mmol/L、SCr 162.3±26.4 μmol/L,高于非高氯血症组的5.9±1.1 mmol/L和78.6±9.2 μmol/L。
  • 高氯血症组总住院天数10.2±1.6天、ICU住院天数6.2±1.0天,长于非高氯血症组的5.6±1.2天和3.1±0.6天。

适用人群与场景

  • 2019年6月至2021年6月苏州大学附属第一医院首次确诊的急性胰腺炎患者,发病时间<72小时,共162例。
  • 按住院后是否发生MAKE30分为MAKE30组(32例)和非MAKE30组(130例)。

诊断标准与关键阈值

  • MAKE30定义为全因死亡、新发肾脏替代治疗(RRT)和持续性肾功能不全(PRD)。
  • 按入住时血Cl-水平分为高氯血症组(Cl-≥110 mmol/L,n=19)和非高氯血症组(Cl-<110 mmol/L,n=143)。

研究设计与关键结果

  • 回顾性队列研究,纳入162例首次确诊、发病<72小时的AP患者,比较MAKE30组(32例)与非MAKE30组(130例)入住时临床资料。
  • 单因素分析显示,MAKE30组入住时BMI、重症AP比例、APACHE II评分、SOFA评分、BUN、SCr、CRP、HCO3-、Cl-水平及高氯血症比例均较非MAKE30组显著升高。
  • 多因素Logistic回归显示,入住时APACHE II评分(OR=1.659,95%CI 1.426-1.956,P=0.009)、SOFA评分(OR=1.501,95%CI 1.236-1.840,P=0.014)和高氯血症(OR=1.858,95%CI 1.564-2.231,P=0.004)是MAKE30的独立危险因素。
  • 建立MAKE30回归方程:Logit(P)=0.063+0.525×APACHE II评分+0.328×SOFA评分+0.895×高氯血症,作为MAKE30定量预测模型。
  • ROC曲线分析显示,该模型预测MAKE30的AUC为0.846(95%CI 0.774-0.923,P=0.001)。
  • 高氯血症组(n=19)与非高氯血症组(n=143)比较:MAKE30发生率68.4% vs. 13.3%,AKI发生率89.5% vs. 43.4%。
  • 高氯血症组入住时BUN 9.3±2.5 mmol/L vs. 非高氯血症组5.9±1.1 mmol/L,SCr 162.3±26.4 μmol/L vs. 78.6±9.2 μmol/L。
  • 高氯血症组总住院天数10.2±1.6天 vs. 非高氯血症组5.6±1.2天,ICU住院天数6.2±1.0天 vs. 3.1±0.6天。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为MAKE30可作为评估AP患者短期临床预后的重要指标。
  • 作者认为入住时APACHE II评分、SOFA评分和高氯血症是AP患者MAKE30的主要危险因素,基于这三项指标的MAKE30风险模型具有良好的预测性能。
  • 作者认为合并高氯血症的AP患者发生MAKE30的风险高,临床中应高度重视。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the risk factors of major adverse kidney events within 30 days (MAKE30) in patients with acute pancreatitis (AP).

METHODS: A retrospective cohort study was conducted. A total of 162 patients who were first diagnosed with AP in the First Affiliated Hospital of Soochow University from June 2019 to June 2021 and the onset time was less than 72 hours were enrolled. Patients were divided into MAKE30 group and non-MAKE30 group according to the occurrence of MAKE30 after hospitalization. MAKE30 was defined as death from any cause, new renal replacement therapy (RRT), and persistent renal insufficiency (PRD). The clinical data of the two groups at admission were compared. The independent risk factors of MAKE30 were analyzed by multivariate Logistic regression method, and a regression equation was established as a quantitative prediction model of MAKE30. Receiver operator characteristic curve (ROC curve) was drawn to analyze the prediction of the quantitative prediction model value.

RESULTS: All 162 patients were included in the final analysis, including 32 in the MAKE30 group and 130 in the non-MAKE30 group. Univariate analysis showed that compared with the non-MAKE30 group, the body mass index (BMI), the proportion of severe AP, and the acute physiology and chronic health evaluation II (APACHE II) score, the sequential organ failure assessment (SOFA) score, blood urea nitrogen (BUN), serum creatinine (SCr), C-reactive protein (CRP), HCO3-, Cl- levels and the proportion of hyperchloremia at admission in the MAKE30 group were significantly increased. Multivariate Logistic regression analysis showed that APACHE II score at admission [odds ratio (OR) = 1.659, 95% confidence interval (95%CI) was 1.426-1.956, P = 0.009], SOFA score (OR = 1.501, 95%CI was 1.236-1.840, P = 0.014) and hyperchloremia (OR = 1.858, 95%CI was 1.564-2.231, P = 0.004) were independent risk factors for MAKE30 in AP patients. The MAKE30 regression equation was established by the above risk factors [Logit(P) = 0.063+0.525×APACHE II score+0.328×SOFA score+0.895×hyperchloremia], which was used as the MAKE30 quantitative prediction model. ROC curve analysis showed that the area under the ROC curve (AUC) of the model for predicting MAKE30 was 0.846 (95%CI was 0.774-0.923, P = 0.001). The patients were divided into two subgroups with hyperchloremia (Cl- ≥ 110 mmol/L, n = 19) and non-hyperchloremia (Cl- < 110 mmol/L, n = 143) according to the blood Cl- level at admission. The incidence of MAKE30 and acute kidney injury (AKI) in the hyperchloremia group was significantly increased (MAKE30: 68.4% vs. 13.3%, AKI: 89.5% vs. 43.4%), and the levels of BUN and SCr at admission were significantly increased [BUN (mmol/L): 9.3±2.5 vs. 5.9±1.1, SCr (μmol/L): 162.3±26.4 vs. 78.6±9.2], the total length of hospital stay and length of intensive care unit (ICU) stay were significantly longer [total length of hospital stay (days): 10.2±1.6 vs. 5.6±1.2, length of ICU stay (days): 6.2±1.0 vs. 3.1±0.6], the cumulative intravenous infusion volume increased significantly at 48 hours and 72 hours (mL: 7 235.9±1 025.3 vs. 5 659.6±956.7 at 48 hours, 11 052.6±1 659.8 vs. 7 156.9±1 052.4 at 72 hours), differences were statistically significant (all P < 0.01).

CONCLUSIONS: MAKE30 can be used as an important indicator to evaluate the short-term clinical prognosis of AP patients. APACHE II score, SOFA score and hyperchloremia at admission are the main risk factors. The risk model of MAKE30 based on these three indicators has good predictive performance. AP patients with hyperchloremia are at high risk of developing MAKE30, which should be highly regarded in clinical practice.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Gao L, Xu Y, Fei W, et al. [Analysis of risk factors of major adverse kidney events within 30 days in patients with acute pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36100411. doi:10.3760/cma.j.cn121430-20211206-01835

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。